145660-99-7

Basic information

• Product Name: 2-Benzyloxycarbonyl-3R-isobutyl-succinic acid 4-tert-butyl ester 1-benzyl ester
• Synonyms: 2-Benzyloxycarbonyl-3R-isobutyl-succinic acid 4-tert-butyl ester 1-benzyl ester
• CAS NO: 145660-99-7
• Molecular Weight: 454.563
• Mol File: 145660-99-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-Benzyloxycarbonyl-3R-isobutyl-succinic acid 4-tert-butyl ester 1-benzyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Benzyloxycarbonyl-3R-isobutyl-succinic acid 4-tert-butyl ester 1-benzyl ester(145660-99-7)
• EPA Substance Registry System: 2-Benzyloxycarbonyl-3R-isobutyl-succinic acid 4-tert-butyl ester 1-benzyl ester(145660-99-7)

Safety Data

• Hazardous Substances Data: 145660-99-7(Hazardous Substances Data)

Upstream product

• 15014-25-2 malonic acid dibenzyl ester 
• 130464-88-9 (2R)-2-bromo-4-methylpentanoic acid t-butyl ester 
• 152624-22-1 2-bromo-4-methylpentanoic acid t-butyl ester 
• 165172-57-6 2-benzyloxycarbonyl-3(R)-hydroxycarbonyl-5-methylhexanoic acid benzyl ester 
• 42990-28-3 (R)-2-bromo-4-methylpentanoic acid 

Downstream Products

• 165172-57-6 2-benzyloxycarbonyl-3(R)-hydroxycarbonyl-5-methylhexanoic acid benzyl ester 
• 168158-38-1 (2R,3S)-N⁴-Benzyloxy-2-isobutyl-3-methyl-N¹-((S)-methylcarbamoyl-phenyl-methyl)-succinamide 
• 168158-16-5 (2R,3R)-N⁴-Hydroxy-2-isobutyl-3-methyl-N¹-((S)-methylcarbamoyl-phenyl-methyl)-succinamide 
• 168158-16-5 KB-R₇₇₈₅ 
• 188728-97-4 (R)-2,5-Dimethyl-3-[((S)-methylcarbamoyl-phenyl-methyl)-carbamoyl]-hexanoic acid 
• 188728-83-8 (R)-2-(3,4-Dihydro-1H-isoquinolin-2-ylmethyl)-5-methyl-3-((S)-1-methylcarbamoyl-2-naphthalen-1-yl-ethylcarbamoyl)-hexanoic acid benzyl ester 
• 188729-13-7 2-[(R)-3-Methyl-1-((S)-1-methylcarbamoyl-2-naphthalen-1-yl-ethylcarbamoyl)-butyl]-malonic acid dibenzyl ester 
• 190909-32-1 (2R,3R)-N¹-Benzyloxy-2-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-3-isobutyl-N⁴-((S)-methylcarbamoyl-phenyl-methyl)-succinamide 
• 190909-11-6 (2R,3R)-N⁴-Benzyloxy-2-isobutyl-N¹-((S)-methylcarbamoyl-phenyl-methyl)-3-(4-methyl-piperazin-1-ylmethyl)-succinamide 
• 168158-24-5 (2R,3R)-N⁴-Benzyloxy-2-isobutyl-N¹-((S)-methylcarbamoyl-phenyl-methyl)-3-morpholin-4-ylmethyl-succinamide 
• 168158-25-6 2-{(R)-3-Methyl-1-[((S)-methylcarbamoyl-phenyl-methyl)-carbamoyl]-butyl}-malonic acid dibenzyl ester 
• 188728-80-5 (R)-5-Methyl-3-((S)-1-methylcarbamoyl-2-naphthalen-1-yl-ethylcarbamoyl)-2-methylene-hexanoic acid benzyl ester 

Relevant articles and documents

Matrix metalloproteinase inhibitors

A compound of formula (I), wherein W is —NHOH or —OH, R1is either free or protected hydroxymethyl or mercaptomethyl or derivatives thereof, R2is free or protected hydroxy, R3and R4is an organic group, R5/s

Synthesis and biological evaluation of orally active matrix metaloproteinase inhibitors

The synthesis and biological evaluation of orally active inhibitors of matrix metalloproteinase are reported. Modifications of the P2' position and the α-substituent of hydroxamic acid derivatives were carried out, and revealed that the P2' substituent influenced the MMP inhibitory activities in vitro and in plasma after oral administration. The hydroxamates with phenylglycine at the P2' position were absorbed well orally. Compound 15e, which exhibited the longest duration of inhibitory activity in plasma after oral administration among the phenylglycine derivatives (5a-5d, 15a, 15c, 15e), was evaluated in a rat adjuvant arthritis model. A reduction in hind foot pad swelling and improvements of some inflammatory parameters were demonstrated when the compound was administered orally. These results indicate the potential of MMP inhibitors for rheumatoid arthritis.